News & Updates
Filter by Specialty:

Off-label targeted drugs improve survival in CTEPH
Off-label pulmonary arterial hypertension (PAH)-targeted drugs may increase long-term survival in patients with chronic thromboembolic pulmonary hypertension (CTEPH), as shown in a study.
Off-label targeted drugs improve survival in CTEPH
26 Jun 2024
Working out in the COVID aftermath: How intense can one go?
Outpatients with post-COVID condition (PCC) generally tolerated exercise without significant worsening of symptoms or decline in aerobic performance after 48 hours. However, they had lower muscle strength and aerobic capacity than controls, and even showed signs of POTS* and myopathy in a randomized crossover trial.
Working out in the COVID aftermath: How intense can one go?
26 Jun 2024
Lung ultrasound helps rule out ILD in patients with RA
Lung ultrasound (LUS), a low-cost tool with a high negative predictive value, can be a useful instrument for dismissing the presence of interstitial lung disease (ILD) in patients with rheumatoid arthritis (RA), suggests a study.
Lung ultrasound helps rule out ILD in patients with RA
25 Jun 2024
Subcutaneous amivantamab compares favourably with intravenous dosing in EGFR-mutant NSCLC
In previously treated patients with EGFR-mutated advanced non-small-cell lung cancer (NSCLC), subcutaneous (SC) amivantamab combined with lazertinib shows noninferior pharmacokinetic and efficacy profiles compared with the approved intravenous (IV) formulation of amivantamab, according to the phase III PALOMA-3 trial.